The goal of this type of clinical trial is to learn about symptomatic patients with post-COVID-19 parenchymal lung abnormalities. The main questions it aims to answer are: the efficacy and safety of low-dose dexamethasone or traditional Chinese medicine in symptomatic patients with post-COVID-19 parenchymal lung abnormalities. Participants will be divided into three parallel groups:controlled group with conventional western medicine treatment including oxygen therapy, antibiotics, nebulization therapy, etc. dexamethasone group: dexamethasone 1.5mg/day for one week and 0.75mg/day for another week basing on conventional western medicine. Chinese medicine group: Strengthening spleen and tonifying lung decoction for 2 weeks basing on conventional western medicine.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
420
conventional western medicine treatment only
treat with Dexamethasone for 2 weeks
treat with strengthening spleen and tonifying lung decoction for 2 weeks
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
RECRUITINGLung CT scan
compared with base,≥90% pneumonia obsorbed
Time frame: 1 month
Lung CT scan
compared with base,≥50% pneumonia obsorbed
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.